Calcium Channel Blocker Overdose — High Dose Insulin

Key Points

• CCB poisoning can produce both cardiogenic shock and profound vasoplegia; treatment should address the dominant physiology.
• Verapamil and diltiazem more often cause bradycardia and conduction block, while dihydropyridines often cause severe vasodilation.
• Hyperglycemia is a characteristic clue to significant CCB toxicity.
• Give IV calcium and vasopressors for severe hemodynamic toxicity.
• High-dose insulin is recommended for hypotension in life-threatening CCB poisoning.
• High-dose insulin requires frequent glucose and potassium monitoring and often dextrose supplementation.
• Glucagon has uncertain benefit in CCB poisoning and should not displace high-dose insulin or vasopressors.
• Refractory shock should trigger early consultation with an ECMO-capable center because VA-ECMO can be lifesaving.

Algorithm

1. Stabilize airway and breathing, establish IV or IO access, place on continuous ECG and hemodynamic monitoring, and contact toxicology.
2. Identify the CCB, amount, formulation, ingestion time, coingestants, and baseline cardiac or renal disease.
3. Obtain ECG, glucose, electrolytes, ionized calcium, renal function, lactate, and acid-base assessment; use bedside echocardiography when available.
4. Give cautious isotonic fluid for suspected preload deficit and IV calcium for significant bradycardia, conduction disturbance, or hypotension.
5. Start vasopressor therapy promptly for persistent hypotension and choose agents according to vasoplegic versus cardiogenic physiology.
6. Initiate high-dose insulin with appropriate glucose supplementation and frequent glucose and potassium checks for life-threatening hypotension.
7. Reassess ventricular function, perfusion, lactate, urine output, glucose, potassium, and ionized calcium repeatedly.
8. Consider selected adjuncts such as methylene blue or lipid emulsion only for refractory cases with toxicology input.
9. Escalate early to VA-ECMO or another form of ECLS when shock remains refractory to optimized pharmacologic therapy.
10. Admit significant symptomatic or extended-release poisoning to a monitored critical care setting.

Clinical Synopsis & Reasoning

Calcium channel blocker poisoning produces a spectrum of cardiovascular collapse determined by agent, dose, formulation, and patient physiology. Verapamil and diltiazem have prominent myocardial and atrioventricular nodal effects, causing bradycardia, conduction block, reduced contractility, and hypotension. Dihydropyridines such as amlodipine more often produce profound peripheral vasodilation, although selectivity is lost in large overdoses and myocardial depression can occur. Extended-release products can delay deterioration for many hours, so an initially stable patient may still become critically ill.

Hypotension may reflect both low cardiac output and vasoplegia. Bedside echocardiography can help distinguish a poorly contractile ventricle from a hyperdynamic vasodilatory state and guide vasopressor, inotrope, fluid, and mechanical support decisions. Hyperglycemia is a useful clue because pancreatic beta-cell calcium-channel blockade reduces insulin release and peripheral tissues become relatively insulin resistant. Lactic acidosis, acute kidney injury, altered mental status, pulmonary edema, and shock liver mark severe poisoning.

The diagnosis is usually clinical from the medication history, pill count, formulation, timing, and cardiovascular findings. Obtain an ECG early and repeat it because bradycardia and atrioventricular block may evolve. Evaluate for coingestants that can worsen conduction or hypotension, particularly beta blockers, digoxin, tricyclic antidepressants, and other antihypertensives. A poison center or medical toxicologist should be involved early in any symptomatic or potentially large ingestion.

Treatment Strategy & Disposition

Begin with airway support, oxygenation, IV access, continuous ECG monitoring, and cautious isotonic fluid resuscitation when volume responsiveness is plausible. Avoid repeated large fluid loads in patients developing cardiogenic pulmonary edema. Atropine can be tried for symptomatic bradycardia but is often insufficient. Intravenous calcium can improve contractility and conduction. Calcium chloride delivers more elemental calcium and is preferably given through central access when repeated dosing is anticipated, while calcium gluconate is safer through a peripheral vein. Ionized calcium should be monitored during aggressive replacement.

The 2025 American Heart Association guideline recommends high-dose insulin for hypotension in life-threatening CCB poisoning and vasopressors for hypotension. High-dose insulin improves myocardial carbohydrate utilization and inotropy. A common toxicology approach is a regular insulin bolus followed by a high-dose infusion with dextrose as needed to maintain euglycemia. Glucose must be checked frequently, and potassium should be followed because insulin shifts potassium intracellularly. Hypoglycemia, hypokalemia, and volume overload from concentrated dextrose therapy are foreseeable complications. High-dose insulin should not be withheld merely because the patient is already hyperglycemic.

Vasopressor selection should match physiology. Norepinephrine is often appropriate for vasodilatory shock, while epinephrine may be helpful when bradycardia and myocardial depression are prominent. Multiple agents are sometimes required. Glucagon has an uncertain role in CCB poisoning and should not delay therapies with stronger support. Methylene blue has been used as an adjunct for refractory vasoplegia, particularly after amlodipine overdose, but evidence is limited. Intravenous lipid emulsion is not routine first-line treatment and should be reserved for selected refractory cases with toxicology input.

Patients with refractory cardiogenic or mixed shock despite high-dose insulin, calcium, and vasopressors should be considered early for venoarterial extracorporeal membrane oxygenation in centers capable of providing it. The AHA considers ECLS reasonable for refractory life-threatening CCB poisoning. Gastrointestinal decontamination decisions depend on airway safety, time from ingestion, and extended-release formulation; whole bowel irrigation may be considered in selected large sustained-release ingestions with toxicology guidance. All significant symptomatic overdoses require monitored admission, usually intensive care.

Epidemiology / Risk Factors

• Calcium channel blockers are common cardiovascular medications and remain an important cause of severe prescription-drug poisoning.
• Extended-release verapamil and diltiazem can produce delayed and prolonged cardiotoxicity.
• Amlodipine and other long-acting dihydropyridines can cause profound vasoplegia with a prolonged clinical course.
• Older adults and patients with baseline conduction disease, heart failure, or renal impairment may tolerate toxicity poorly.
• Coingestion with beta blockers or other cardioactive medications can produce more severe bradycardia and shock.

Investigations

Therapy Elements

Pharmacology

Prognosis / Complications

• Early recognition and aggressive targeted treatment can lead to complete recovery even after severe shock.
• Poor prognostic features include refractory hypotension, severe acidosis, rising lactate, multiorgan failure, cardiac arrest, and delayed access to mechanical support.
• Long-acting formulations can require prolonged vasopressor and insulin therapy before drug effects resolve.
• Survivors without prolonged hypoxic injury generally recover cardiac function as the drug clears.
• VA-ECMO can provide a bridge to drug clearance in otherwise refractory but reversible poisoning.

Patient Education / Counseling

• Explain that serious CCB overdose can worsen hours after ingestion, particularly with extended-release products.
• After intentional overdose, arrange psychiatric assessment and safe medication access planning before discharge.
• Review all cardiovascular medications to identify possible coingestants and duplication errors.
• Advise patients and caregivers to store high-risk medications securely and out of reach of children.
• After recovery, medication reintroduction should be coordinated with the treating team rather than resumed automatically.
• Provide poison-center and emergency return guidance for any future suspected ingestion.

Notes

CCB overdose should be managed as a dynamic shock syndrome. Waiting for profound bradycardia before escalating therapy can be dangerous because amlodipine and other dihydropyridines may cause devastating vasoplegia with less striking conduction disease. High-dose insulin should be started early enough to provide benefit before prolonged hypoperfusion develops.

The 2025 AHA toxicology recommendations place high-dose insulin and vasopressors at the center of life-threatening CCB poisoning and support calcium and ECLS as important components of severe-case management. Glucagon has substantially weaker support in CCB poisoning than in beta-blocker poisoning.

References

1. American Heart Association 2025 Guidelines: Life-Threatening Calcium Channel Blocker Poisoning — Link